E. Verna, R. Brown, and . Jr, Hepatitis C and Liver Transplantation: Enhancing Outcomes and Should Patients Be Retransplanted, Clinics in Liver Disease, vol.12, issue.3, pp.637-659, 2008.
DOI : 10.1016/j.cld.2008.03.010

P. Simmonds, J. Bukh, C. Combet, G. Del-eage, N. Enomoto et al., Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes, Hepatology, vol.17, issue.4, pp.962-973, 2005.
DOI : 10.1002/hep.20819

URL : https://hal.archives-ouvertes.fr/hal-00313678

T. Von-hahn, J. Yoon, H. Alter, C. Rice, B. Rehermann et al., Hepatitis C Virus Continuously Escapes From Neutralizing Antibody and T-Cell Responses During Chronic Infection In Vivo, Gastroenterology, vol.132, issue.2, pp.667-678, 2007.
DOI : 10.1053/j.gastro.2006.12.008

J. Mchutchison, M. Manns, A. Muir, N. Terrault, I. Jacobson et al., Telaprevir for Previously Treated Chronic HCV Infection, New England Journal of Medicine, vol.362, issue.14, pp.1292-1303, 2010.
DOI : 10.1056/NEJMoa0908014

C. Sarrazin, C. Zeuzem, S. Pawlotsky, and J. , Antiviral strategies in hepatitis C virus infection, Journal of Hepatology, vol.56, pp.88-100, 2012.
DOI : 10.1016/S0168-8278(12)60010-5

C. Welsch, A. Jesudian, S. Zeuzem, and I. Jacobson, New direct-acting antiviral agents for the treatment of hepatitis C virus infection and perspectives, Gut, vol.61, issue.Suppl 1, pp.36-46, 2012.
DOI : 10.1136/gutjnl-2012-302144

J. Youn, S. Park, D. Lavillette, F. Cosset, S. Yang et al., Sustained E2 antibody response correlates with reduced peak viremia after hepatitis C virus infection in the chimpanzee, Hepatology, vol.74, issue.6, pp.1429-1436, 2005.
DOI : 10.1002/hep.20934

M. Law, T. Maruyama, J. Lewis, E. Giang, A. Tarr et al., Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge, Nature Medicine, vol.78, issue.1, pp.25-27, 2008.
DOI : 10.1016/j.virol.2006.05.015

T. Morin, T. Broering, B. Leav, B. Blair, K. Rowley et al., Human Monoclonal Antibody HCV1 Effectively Prevents and Treats HCV Infection in Chimpanzees, PLoS Pathogens, vol.8, issue.8, p.1002895, 2012.
DOI : 10.1371/journal.ppat.1002895.t004

R. Chung, F. Gordon, M. Curry, T. Schiano, S. Emre et al., Human Monoclonal Antibody MBL-HCV1 Delays HCV Viral Rebound Following Liver Transplantation: A Randomized Controlled Study, American Journal of Transplantation, vol.132, issue.5 Pt 1, 2013.
DOI : 10.1111/ajt.12083

K. Dowd, D. Netski, X. Wang, A. Cox, and S. Ray, Selection Pressure From Neutralizing Antibodies Drives Sequence Evolution During Acute Infection With Hepatitis C Virus, Gastroenterology, vol.136, issue.7, pp.2377-2386, 2009.
DOI : 10.1053/j.gastro.2009.02.080

J. Pestka, M. Zeisel, E. Bl?-aser, P. Sch?-urmann, B. Bartosch et al., Rapid induction of virus-neutralizing antibodies and viral clearance in a single-source outbreak of hepatitis C, Proceedings of the National Academy of Sciences, vol.104, issue.14, pp.6025-6030, 2007.
DOI : 10.1073/pnas.0607026104

URL : https://hal.archives-ouvertes.fr/inserm-00395910

N. Ndongo, P. Berthillon, P. Pradat, C. Vieux, I. Bordes et al., Association of anti-E1E2 antibodies with spontaneous recovery or sustained viral response to therapy in patients infected with hepatitis C virus, Hepatology, vol.461, issue.5, pp.1531-1542, 2010.
DOI : 10.1002/hep.23862

C. Brimacombe, J. Grove, L. Meredith, K. Hu, A. Syder et al., Neutralizing Antibody-Resistant Hepatitis C Virus Cell-to-Cell Transmission, Journal of Virology, vol.85, issue.1, pp.596-605, 2011.
DOI : 10.1128/JVI.01592-10

J. Timpe, Z. Stamataki, A. Jennings, K. Hu, M. Farquhar et al., Hepatitis C virus cell-cell transmission in hepatoma cells in the presence of neutralizing antibodies, Hepatology, vol.7, issue.1, pp.17-24, 2008.
DOI : 10.1002/hep.21959

J. Witteveldt, M. Evans, J. Bitzegeio, G. Koutsoudakis, A. Owsianka et al., CD81 is dispensable for hepatitis C virus cell-to-cell transmission in hepatoma cells, Journal of General Virology, vol.90, issue.1, pp.48-58, 2009.
DOI : 10.1099/vir.0.006700-0

C. Hamers-casterman, T. Atarhouch, S. Muyldermans, G. Robinson, C. Hamers et al., Naturally occurring antibodies devoid of light chains, Nature, vol.363, issue.6428, pp.446-448, 1993.
DOI : 10.1038/363446a0

P. Lafaye, I. Achour, P. England, C. Duyckaerts, and F. Rougeon, Single-domain antibodies recognize selectively small oligomeric forms of amyloid ??, prevent A??-induced neurotoxicity and inhibit fibril formation, Molecular Immunology, vol.46, issue.4, pp.695-704, 2009.
DOI : 10.1016/j.molimm.2008.09.008

M. Harmsen, D. Haard, and H. , Properties, production, and applications of camelid single-domain antibody fragments, Applied Microbiology and Biotechnology, vol.77, issue.1, pp.13-22, 2007.
DOI : 10.1007/s00253-007-1142-2

P. Vanlandschoot, C. Stortelers, E. Beirnaert, L. Iba~-nez, B. Schepens et al., Nanobodies??: New ammunition to battle viruses, Antiviral Research, vol.92, issue.3, pp.389-407, 2011.
DOI : 10.1016/j.antiviral.2011.09.002

B. Thys, L. Schotte, S. Muyldermans, U. Wernery, G. Hassanzadeh-ghassabeh et al., In vitro antiviral activity of single domain antibody fragments against poliovirus, Antiviral Research, vol.87, issue.2, pp.257-264, 2010.
DOI : 10.1016/j.antiviral.2010.05.012

L. Meredith, H. Harris, G. Wilson, N. Fletcher, P. Balfe et al., Early infection events highlight the limited transmissibility of hepatitis C virus in vitro, Journal of Hepatology, vol.58, issue.6, 2013.
DOI : 10.1016/j.jhep.2013.01.019

A. Tarr, R. Urbanowicz, M. Hamed, A. Albecka, C. Mcclure et al., Hepatitis C Patient-Derived Glycoproteins Exhibit Marked Differences in Susceptibility to Serum Neutralizing Antibodies: Genetic Subtype Defines Antigenic but Not Neutralization Serotype, Journal of Virology, vol.85, issue.9, pp.4246-4257, 2011.
DOI : 10.1128/JVI.01332-10

D. Johansson, C. Voisset, A. Tarr, M. Aung, J. Ball et al., Human combinatorial libraries yield rare antibodies that broadly neutralize hepatitis C virus, Proceedings of the National Academy of Sciences, vol.104, issue.41, pp.16269-16274, 2007.
DOI : 10.1073/pnas.0705522104

K. Vu, M. Ghahroudi, L. Wyns, and S. Muyldermans, Comparison of llama VH sequences from conventional and heavy chain antibodies, Molecular Immunology, vol.34, issue.16-17, pp.1121-1131, 1997.
DOI : 10.1016/S0161-5890(97)00146-6

V. Nguyen, R. Hamers, L. Wyns, and S. Muyldermans, Camel heavy-chain antibodies: diverse germline VHH and specific mechanisms enlarge the antigen-binding repertoire, The EMBO Journal, vol.376, issue.5, pp.921-930, 2000.
DOI : 10.1093/emboj/19.5.921

G. Wedemayer, P. Patten, L. Wang, P. Schultz, and R. Stevens, Structural Insights into the Evolution of an Antibody Combining Site, Science, vol.276, issue.5319, pp.1665-1669, 1997.
DOI : 10.1126/science.276.5319.1665

V. Edwards, A. Tarr, R. Urbanowicz, and J. Ball, The role of neutralizing antibodies in hepatitis C virus infection, Journal of General Virology, vol.93, issue.1, pp.1-19, 2012.
DOI : 10.1099/vir.0.035956-0

S. Ciesek, T. Von-hahn, C. Colpitts, L. Schang, M. Friesland et al., The green tea polyphenol, epigallocatechin-3-gallate, inhibits hepatitis C virus entry, Hepatology, vol.76, issue.6, pp.1947-1955, 2011.
DOI : 10.1002/hep.24610

C. Baldick, M. Wichroski, A. Pendri, A. Walsh, J. Fang et al., A Novel Small Molecule Inhibitor of Hepatitis C Virus Entry, PLoS Pathogens, vol.62, issue.9, p.1001086, 2010.
DOI : 10.1371/journal.ppat.1001086.t005

M. Backovic, D. Johansson, B. Klupp, T. Mettenleiter, M. Persson et al., Efficient method for production of high yields of Fab fragments in Drosophila S2 cells, Protein Engineering Design and Selection, vol.23, issue.4, pp.169-174, 2010.
DOI : 10.1093/protein/gzp088

URL : https://hal.archives-ouvertes.fr/pasteur-00460809

A. Gilmartin, B. Lamp, T. Rumenapf, M. Persson, F. Rey et al., High-level secretion of recombinant monomeric murine and human single-chain Fv antibodies from Drosophila S2 cells, Protein Engineering Design and Selection, vol.25, issue.2, pp.59-66, 2012.
DOI : 10.1093/protein/gzr058

M. Garcia-retortillo, X. Forns, A. Feliu, E. Moitinho, J. Costa et al., Hepatitis C virus kinetics during and immediately after liver transplantation, Hepatology, vol.68, issue.3, pp.680-687, 2002.
DOI : 10.1053/jhep.2002.31773

V. Garg, R. Van-heeswijk, J. Lee, K. Alves, P. Nadkarni et al., Effect of telaprevir on the pharmacokinetics of cyclosporine and tacrolimus, Hepatology, vol.37, issue.10 Suppl 2, pp.20-27, 2011.
DOI : 10.1002/hep.24443

T. Krey, J. Alayer, C. Kikuti, A. Saulnier, L. Damier-piolle et al., The Disulfide Bonds in Glycoprotein E2 of Hepatitis C Virus Reveal the Tertiary Organization of the Molecule, PLoS Pathogens, vol.14, issue.2, p.1000762, 2010.
DOI : 10.1371/journal.ppat.1000762.s005

URL : https://hal.archives-ouvertes.fr/pasteur-00460826

L. Kong, E. Giang, J. Robbins, R. Stanfield, D. Burton et al., Structural basis of hepatitis C virus neutralization by broadly neutralizing antibody HCV1, Proceedings of the National Academy of Sciences, vol.109, issue.24, pp.9499-9504, 2012.
DOI : 10.1073/pnas.1202924109

A. Tarr, A. Owsianka, J. Timms, C. Mcclure, R. Brown et al., Characterization of the hepatitis C virus E2 epitope defined by the broadly neutralizing monoclonal antibody AP33, Hepatology, vol.399, issue.3, pp.592-601, 2006.
DOI : 10.1002/hep.21088

Z. Keck, A. Saha, J. Xia, Y. Wang, P. Lau et al., Mapping a Region of Hepatitis C Virus E2 That Is Responsible for Escape from Neutralizing Antibodies and a Core CD81-Binding Region That Does Not Tolerate Neutralization Escape Mutations, Journal of Virology, vol.85, issue.20, pp.10451-10463, 2011.
DOI : 10.1128/JVI.05259-11

URL : https://hal.archives-ouvertes.fr/pasteur-00630502

F. Helle, G. Duverlie, and J. Dubuisson, The Hepatitis C Virus Glycan Shield and Evasion of the Humoral Immune Response, Viruses, vol.3, issue.12, pp.1909-1932, 2011.
DOI : 10.3390/v3101909

Q. Sattentau, Avoiding the void: cell-to-cell spread of human viruses, Nature Reviews Microbiology, vol.73, issue.11, pp.815-826, 2008.
DOI : 10.1038/nrmicro1972